SCHEMBL87466

SCHEMBL87466

c1cnc(-c2ncc[nH]2)nc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 2/20 0.54
MTOR P42345 1/20 0.54
ADK P55263 1/20 0.54
ALDH1A1 P00352 4/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
KDM4E B2RXH2 2/20 0.44
CSNK1A1 P48729 1/20 0.40
TYRO3 Q06418 1/20 0.40
DYRK1B Q9Y463 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ADRA2A P08913 1/20 0.40
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
SMPD3 Q9NY59 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3069705 0.97 NISCH (0.52) NISCHMTORADKALDH1A1MEN1
SCHEMBL9026316 0.81 NISCH (0.50) NISCHMTORADKALDH1A1MEN1
SCHEMBL13977589 0.81 NISCH (0.50) NISCHMTORADKALDH1A1MEN1
SCHEMBL252307 0.80 NISCH (0.45) NISCHMTORADKALDH1A1MEN1
SCHEMBL81650 0.80 NISCH (0.59) NISCHMTORADKALDH1A1MEN1
Hydrochloric Acid SCHEMBL1536214 0.77 NISCH (0.56) NISCHMTORADKALDH1A1MEN1
SCHEMBL28425230 0.77 NISCH (0.56) NISCHMTORADKALDH1A1MEN1
SCHEMBL20357190 0.73 NISCH (0.39) NISCHMTORADKALDH1A1MEN1
SCHEMBL28405292 0.73 NISCH (0.43) NISCHMTORADKALDH1A1MEN1
SCHEMBL20595289 0.72 ALDH1A1 (0.43) NISCHMTORADKALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115490668-B Pyrimidylimidazole compound, preparation method thereof and organic solderability preservative 深圳市贝加电子材料有限公司 2024-04-02 CN claimed
WO-2023205507-A1 ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE ESSA PHARMA INC. (CA) 2023-10-26 WO claimed
CN-115490668-A Pyrimidyl imidazole compound, preparation method thereof and organic weldable protective agent 深圳市贝加电子材料有限公司 2022-12-20 CN claimed
WO-2025149577-A1 18F-CXCR2 PET TRACER JULIUS-MAXIMILIANS-UNIVERSITAET WUERZBURG (DE) 2025-07-17 WO disclosed
WO-2025133653-A1 IMIDAZOLE DERIVATIVES AND USE THEREOF AS ANTIFIBROTIC AGENTS VICHEM CHEMIE KUTATÓ KFT. (HU) 2025-06-26 WO disclosed
US-20250099453-A1 USE OF NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS FOR IMMUNOTHERAPY IN MELANOMA PATIENTS UNIV NORTHWESTERN (US) 2025-03-27 US disclosed
US-12083113-B2 Use of neuronal nitric oxide synthase inhibitors for immunotherapy in melanoma patients NORTHWESTERN UNIVERSITY (US) 2024-09-10 US disclosed
CN-112933094-B Methods and compositions for preventing and treating hearing loss 听治疗有限责任公司 2024-07-26 CN disclosed
US-20240206208-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2024-06-20 US disclosed
EP-4362646-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES Universal Display Corporation (US) 2024-05-01 EP disclosed
CN-117956822-A Organic electroluminescent material and device 环球展览公司 2024-04-30 CN disclosed
CN-1378544-A Substituted azoles compounds NOVARTIS AG (CH) 2002-11-06 CN disclosed
US-20020120139-A1 Pyrimidinone compounds and pharmaceutical compositions containing them HICKEY DEIRDRE MARY BERNADETTE (GB) 2002-08-29 US disclosed
WO-2002050062-A2 BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS NEUROGEN CORPORATION (US) 2002-06-27 WO disclosed
US-20020032183-A1 Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as JNK-inhibitors LOGRASSO PHILIP (US) 2002-03-14 US disclosed
US-20020032183-A1 Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as JNK-inhibitors LOGRASSO PHILIP (US) 2002-03-14 US disclosed
WO-2001091749-A1 USE OF (DI-SUBSTITUTED-PHENYL)-PYRIMIDINYL-IMIDAZOLE DERIVATIVES AS JNK-INHIBITORS MERCK & CO., INC. (US) 2001-12-06 WO disclosed
US-6180355-B1 Method for diagnosing and treating chronic pelvic pain syndrome UNIVERSITY OF MARYLAND, BALTIMORE 2001-01-30 US disclosed
US-5916891-A CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION (US) 1999-06-29 US disclosed
US-5663334-A CYTOKINE INHIBITORS FORMED BY REACTION OF IMINE WITH SULFUR SUBSTITUTED NITRILE SMITHKLINE BEECHAM CORPORATION (US) 1997-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120139-A1 Pyrimidinone compounds and pharmaceutical compositions containing them PLA2G7, PLA2G1B, PLA2G4C NISCH 1963/4885MTOR 2468/4885ADK 863/4885
US-20020032183-A1 Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as JNK-inhibitors MAP2, DCX, BAD NISCH 1129/4885MTOR 373/4885ADK 1411/4885
US-20250099453-A1 USE OF NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS FOR IMMUNOTHERAPY IN MELANOMA PATIENTS NOS2, NOS1, NOS3 NISCH 1985/4885MTOR 926/4885ADK 1683/4885
US-12083113-B2 Use of neuronal nitric oxide synthase inhibitors for immunotherapy in melanoma patients NOS2, NOS1, NOS3 NISCH 1985/4885MTOR 926/4885ADK 1683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.